Tate Denise G, Rodriguez Gianna M, Sullivan Elizabeth, Forchheimer Martin, Troost Jonathan, Gravelin Misty, Cameron Anne P
Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Michigan Institute for Clinical and Health Research (MICHR), Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Neurourol Urodyn. 2025 Apr;44(4):829-838. doi: 10.1002/nau.70037. Epub 2025 Mar 17.
Recurrent urinary tract infections (UTIs) are common and source of significant morbidity for patients with spinal cord injury/disease (SCI/D) who require clean intermittent catheterization (CIC) bladder management. The purpose of this study was to examine the effectiveness of gentamicin bladder instillations in reducing recurrent UTIs and their impact on neurogenic bladder and bowel (NBB) symptoms and common complications; on quality of life (QOL) and community participation for patients with SCI/D performing CIC.
This is a Prospective single arm feasibility trial of gentamicin bladder instillations. The 6 month intervention consisted of nightly bladder instillations of 30 mg of gentamicin diluted in 50 mL of normal saline. Participants underwent blood and urine testing and completed patient reported measures, both before and after treatment. The primary outcome was the count of UTIs compared across time points (pre-, during and post-treatment) using an UTI incidence rate ratio and paired t tests. Qualitative data was collected post-treatment.
Twenty-one participants enrolled and 11 completed the trial. The rate of UTIs per person per month decreased significantly over time. Before treatment, the total number of UTIs was 35 (0.53 UTI per person per month); during treatment was 6 (0.09 per person per month) and at follow up, 13 (0.18 per person per month). QOL improved significantly with exception of satisfaction with role activities and community participation. There were no significant changes in NBB symptoms and related complications. Participants reported few adverse events (AEs) and qualitative data indicated high overall treatment satisfaction.
Gentamicin instillations were effective in reducing the rate of UTIs by 83% and improving QOL. Findings helped identify potential challenges and opportunities for future studies.
复发性尿路感染(UTI)很常见,对于需要清洁间歇性导尿(CIC)膀胱管理的脊髓损伤/疾病(SCI/D)患者来说,是导致严重发病的原因。本研究的目的是检验庆大霉素膀胱灌注在减少复发性UTI方面的有效性,及其对神经源性膀胱和肠道(NBB)症状及常见并发症的影响;对进行CIC的SCI/D患者生活质量(QOL)和社区参与度的影响。
这是一项关于庆大霉素膀胱灌注的前瞻性单臂可行性试验。为期6个月的干预措施包括每晚用50mL生理盐水稀释30mg庆大霉素进行膀胱灌注。参与者在治疗前后均接受了血液和尿液检测,并完成了患者报告的测量。主要结局是使用UTI发病率比和配对t检验,比较不同时间点(治疗前、治疗期间和治疗后)的UTI计数。治疗后收集了定性数据。
21名参与者入组,11名完成了试验。每人每月的UTI发生率随时间显著下降。治疗前,UTI总数为35次(每人每月0.53次);治疗期间为6次(每人每月0.09次),随访时为13次(每人每月0.18次)。除了对角色活动和社区参与的满意度外,QOL有显著改善。NBB症状和相关并发症没有显著变化。参与者报告的不良事件(AE)很少,定性数据表明总体治疗满意度很高。
庆大霉素灌注在将UTI发生率降低83%和改善QOL方面有效。研究结果有助于确定未来研究的潜在挑战和机遇。